Viewing Study NCT04467905

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 3:27 AM
Ignite Modification Date: 2026-03-03 @ 1:10 AM
Study NCT ID: NCT04467905
Status: COMPLETED
Last Update Posted: 2024-09-19
First Post: 2020-07-08
Is NOT Gene Therapy: True
Has Adverse Events: True
Brief Title: ReVeRA-201: Etripamil in Atrial Fibrillation, Phase 2
Sponsor: Milestone Pharmaceuticals Inc.
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Atrial Fibrillation View
Keywords:

Keywords

Keyword Brief Keyword Text View
None atrial fibrillation View
None ventricular rate control View
None rapid ventricular rate View
None etripamil View